突触核蛋白α(SNCa)多克隆抗体
Polyclonal Antibody to Synuclein Alpha (SNCa)
SNC-A; aSYN; PD1; PARK1; PARK4; NACP; Non-A Beta Component Of Alzheimer's Disease Amyloid Precursor Protein; Non-A4 component of amyloid precursor
- 编号PAB222Hu01
- 物种Homo sapiens (Human,人) 相同的名称,不同的物种。
- 来源多抗制备
- 宿主兔
- 效价-
- Ig类型 IgG
- 纯化方式抗原特异性亲和纯化
- 标记物无标记物
- 免疫原 RPB222Hu01-突触核蛋白α(SNCa)重组蛋白
- 缓冲液成份0.01M 磷酸盐缓冲液(pH7.4,containing 0.05% Proclin-300,50% glycerol)
- 性状液体
- 浓度0.5mg/ml
- 且适物种Mus musculus (Mouse,小鼠), Rattus norvegicus (Rat,大鼠)
- 应用WB; IHC; ICC; IP.
如果抗体需用于流式细胞术,请参见流式抗体。 - 下载 英文说明书 中文说明书
- 规格 20µl100µl 200µl 1ml 10ml
- 价格 ¥ 598 ¥ 1394 ¥ 1992 ¥ 4980 ¥ 19920
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
该抗体是针对SNCa的兔多克隆抗体。在免疫组织化学染色和免疫印迹实验中能识别SNCa。
用法
Western blotting: 0.01-2µg/mL;
Immunohistochemistry: 5-20µg/mL;
Immunocytochemistry: 5-20µg/mL;
Optimal working dilutions must be determined by end user.
储存
经常使用则4°C保存。-20°C保存不超过两年。避免反复冻融。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
赠品
增值服务
相关产品
编号 | 适用物种:Homo sapiens (Human,人) | 应用(仅供研究使用,不用于临床诊断!) |
RPB222Hu01 | 突触核蛋白α(SNCa)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB222Hu01 | 突触核蛋白α(SNCa)多克隆抗体 | WB; IHC; ICC; IP. |
LAB222Hu71 | 突触核蛋白α(SNCa)多克隆抗体(生物素标记) | WB; IHC; ICC. |
MAB222Hu22 | 突触核蛋白α(SNCa)单克隆抗体 | WB; IHC; ICC; IP. |
SEB222Hu | 突触核蛋白α(SNCa)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
AEB222Hu | 抗突触核蛋白α抗体(Anti-SNCa)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
参考文献
杂志 | 参考文献 |
The Journal of Clinical Investigation | Cerebrospinal fluid–based kinetic biomarkers of axonal transport in monitoring neurodegeneration [PubMed: PMC3428100] |
Neurobiology of Disease | Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission [PubMed: PMC3107939] |
Nature Communications | Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus [PubMed: PMC3265381] |
Provisional chapter | Mutations of PARK Genes and Alpha-Synuclein and Parkin Concentrations in Parkinson’s Disease [Intechopen:Source] |
Nerodegeneration | Apolipoprotein Eε4: A Biomarker for Executive Dysfunction among Parkinson's Disease Patients with Mild Cognitive Impairment [pubmed:29326545] |
Experimental gerontology | The anti-aging protein klotho alleviates injury of nigrostriatal dopaminergic pathway in 6-hydroxydopamine rat model of Parkinson's disease: Involvement of PKA/CaMKII/CREB signaling. [pubmed:29107062] |
Neurobiology of Disease | Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity [Pubmed: 30521842] |
molecular and cellular biochemistry | Potential therapeutic effects of antagonizing adenosine A2A receptor, curcumin and niacin in rotenone-induced Parkinson's disease mice model [Pubmed: 31820278] |
International Journal of Pharmacology | Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson's disease [Pubmed: 32084576] |
EBioMedicine | Anti-α-synuclein ASO delivered to monoamine neurons prevents α-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys [Pubmed: 32810825] |
留言咨询